Grants and Contributions
About this information
In June 2016, as part of the Open Government Action Plan, the Treasury Board of Canada Secretariat (TBS) committed to increasing the transparency and usefulness of grants and contribution data and subsequently launched the Guidelines on the Reporting of Grants and Contributions Awards, effective April 1, 2018.
The rules and principles governing government grants and contributions are outlined in the Treasury Board Policy on Transfer Payments. Transfer payments are transfers of money, goods, services or assets made from an appropriation to individuals, organizations or other levels of government, without the federal government directly receiving goods or services in return, but which may require the recipient to provide a report or other information subsequent to receiving payment. These expenditures are reported in the Public Accounts of Canada. The major types of transfer payments are grants, contributions and \'other transfer payments\'.
Included in this category, but not to be reported under proactive disclosure of awards, are (1) transfers to other levels of government such as Equalization payments as well as Canada Health and Social Transfer payments. (2) Grants and contributions reallocated or otherwise redistributed by the recipient to third parties; and (3) information that would normally be withheld under the Access to Information Act and the Privacy Act.
$44,400.00
Nov 1, 2024
For-profit organization
Pre-clinical R and D of a novel non-opioid drug for the treatment of chronic pain
1024974
The company has validated its’ proprietary compounds on this new pain therapy target and the current project will concentrate on the chemical synthesis and biological validation studies to identify and develop back-up compounds as a risk mitigation strategy for the lead compounds currently in development.
$15,000.00
Oct 25, 2024
For-profit organization
Develop digital adoption plan
$400,000.00
Oct 20, 2024
Not-for-profit organization or charity
Breaking the solid tumour barrier with mesothelin-specific CAR-T cells and engineered cytokine signaling to enable effective, safe and affordable cancer therapy.
1020483
Immunotherapy has yielded disappointing results against ovarian cancer, prompting the need for bold new approaches. Chimeric Antigen Receptor (CAR) T cells have proven phenomenally successful against blood cancers but show poor efficacy against solid tumours. The NRC has created a nanobody-based, mesothelin-specific CAR (MesoCAR) to treat ovarian, pancreatic and other cancers. With Innovakine Therapeutics, the PI has developed an engineered cytokine receptor system that enables potent, clinician-controlled amplification of T cell responses in vivo. It is proposed to combine these technologies to create a Canadian-made CAR-T cell product that is safe, effective and affordable for the treatment of ovarian cancer. The project will engage in pre-clinical studies to assess the efficacy, safety and mechanistic features of this innovative therapeutic strategy and to develop cost-effective manufacturing methods for future clinical use. The project team is well-positioned to advance this world-first approach to early-stage, near-term clinical trials for the benefit of ovarian cancer patients.
$15,000.00
Oct 11, 2024
For-profit organization
Develop digital adoption plan
$30,000.00
Oct 1, 2024
Individual or sole proprietorship
PRIZE - Project Grant - PA: Maud Menten - Clinical Research
179361
.
• Commitment A: Enabling Genomic Medicine
• Commitment B: Improving Genetic Disease Diagnosis and Therapies
• Commitment C: Embracing Diversity, Inclusion and Indigenous Rights
• Commitment D: Strengthening the Community
$30,000.00
Oct 1, 2024
Individual or sole proprietorship
PRIZE - Project Grant - PA: Maud Menten - Biomedical Research
179360
.
• Commitment A: Enabling Genomic Medicine
• Commitment B: Improving Genetic Disease Diagnosis and Therapies
• Commitment C: Embracing Diversity, Inclusion and Indigenous Rights
• Commitment D: Strengthening the Community
$15,000.00
Oct 1, 2024
For-profit organization
Develop digital adoption plan
$14,999.40
Sep 13, 2024
For-profit organization
FR-27045
FR-27045
Develop digital adoption plan
$204,387.00
Sep 5, 2024
Not-for-profit organization or charity
Non-Viral Gene Therapy for Myotubular Myopathy: Skeletal Muscle Targeted
Lipid Nanoparticle-Mediated Delivery of the MTM1 Gene to Restore Muscle
Function.
1025235
Myotubular myopathy is a severe congenital disorder marked by muscle
weakness and hypotonia due to mutations in the MTM1 gene, which encodes
myotubularin. This protein is crucial for muscle cell maintenance and repair, and
its deficiency disrupts these processes, causing significant muscle dysfunction.
Current treatments are symptomatic and fail to address the genetic cause,
necessitating therapies that target the root of the disease. Gene therapy,
particularly with viral vectors, shows promise but has limitations such as immune
responses and high costs. Recent safety setbacks in AAV8-MTM1 gene therapy
trials underscore the need for alternative delivery methods.
$30,000.00
Sep 2, 2024
For-profit organization
Bio Data Scientists
1022113
The project aims to hire a Bio Data scientist to optimize the manufacturing processes for cell and gene therapy by identifying the optimal production conditions.